Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report

Atezolizumab in combination with carboplatin plus nab‐paclitaxel for managing combined large‐cell neuroendocrine carcinoma: A case report

Abstract Large‐cell neuroendocrine carcinomas (LCNECs), categorized as high‐grade neuroendocrine carcinomas, account for approximately 3% of resected lung cancers. LCNECs containing other components are called ‘combined LCNECs’ and have no standard treatment. A 73‐year‐old male with a metastatic bra...

Full description

Bibliographic Details
Main Authors: Rei Tsutsumi, Nobutaka Kataoka, Yusuke Kunimatsu, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Respirology Case Reports
Subjects:
atezolizumab
chemoimmunotherapy
combined large‐cell neuroendocrine carcinoma (combined LCNEC)
nab‐paclitaxel
pleomorphic carcinoma
Online Access:https://doi.org/10.1002/rcr2.989

Similar Items

Similar Items